Cronos Group Inc CRON shares are trading lower by 8.93% to $2.80 Monday morning after the company reported worse-than-expected third-quarter results.
What Happened?
Cronos Group reported quarterly losses of 10 cents per share which missed the analyst consensus estimate of a loss of 6 cents by 66.67 percent. The company also reported quarterly sales of $20.92 million which missed the analyst consensus estimate of $24.72 million by 15%. This is a 2.5% increase over sales of $20.41 million in the same period last year.
What Else?
"Market share gains through borderless innovation and cost rationalization were key drivers to this quarter's success," said Mike Gorenstein, Chairman, President and CEO, Cronos.
"While executing on our innovation pipeline, we also remain on track for the previously announced $20 to $25 million in operating expense savings for 2022," added Gorenstein.
According to data from Benzinga Pro, CRON has a 52-week high of $15.60 and a 52-week low of $8.42.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.